MetaADEDB 2.0 @ LMMD
Dihydroergotamine
(ADYPXRFPBQGGAH-UMYZUSPBSA-N)
Structure
SMILES
CS(=O)(=O)O.CN1C[C@@H](C[C@H]2[C@H]1Cc1c[nH]c3c1c2ccc3)C(=O)N[C@]1(C)O[C@@]2(N(C1=O)[C@@H](Cc1ccccc1)C(=O)N1[C@H]2CCC1)O
Molecular Formula:
C34H41N5O8S
Molecular Weight:
679.783
Log P:
2.8705
Hydrogen Bond Acceptor:
12
Hydrogen Bond Donor:
4
TPSA:
180.96
CAS Number(s):
6190-39-2
Synonym(s)
1.
Dihydroergotamine
2.
Agit
3.
Angionorm
4.
Clavigrenin
5.
D-Tamin Retard L.U.T.
6.
D.H.E. 45
7.
DET MS
8.
DHE-45
9.
DHE-Puren
10.
DHE-Ratiopharm
11.
Dihydergot
12.
Dihydroergotamin AL
13.
Dihydroergotamine Mesylate
14.
Dihydroergotamine Methanesulfonate
15.
Dihydroergotamine-Sandoz
16.
Dihytamin
17.
Erganton
18.
Ergomimet
19.
Ergont
20.
Ergotam Von Ct
21.
Ikaran
22.
Migranal
23.
Orstanorm
24.
Seglor
25.
Tamik
26.
Verladyn
27.
D Tamin Retard L.U.T.
28.
DHE 45
29.
DHE Puren
30.
DHE Ratiopharm
31.
DHE45
32.
Dihydroergotamine Sandoz
33.
Mesylate, Dihydroergotamine
34.
Methanesulfonate, Dihydroergotamine
35.
Von Ct, Ergotam
External Link(s)
MeSHD004087
PubChem Compound71171
44155030
ChEBI59756
CHEMBLCHEMBL1200517
KEGGdr:D02211
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 7US FAERS
2Product packaging issueFAERS: 3US FAERS
3Abdominal PainFAERS: 2US FAERS
4AstheniaFAERS: 2US FAERS
5Chest PainFAERS: 2US FAERS
6Deep Vein ThrombosisFAERS: 2US FAERS
7Drug exposure during pregnancyFAERS: 2US FAERS
8FatigueFAERS: 2US FAERS
9Injection site bruisingFAERS: 2US FAERS
10MalaiseFAERS: 2US FAERS
11Medication ErrorFAERS: 2US FAERS
12Myocardial InfarctionFAERS: 2US FAERS
13NauseaFAERS: 2US FAERS
14OverdoseFAERS: 2US FAERS
15Product container issueFAERS: 2US FAERS
16Suicide attemptFAERS: 2US FAERS
17Therapeutic response unexpectedFAERS: 2US FAERS
18ThrombosisFAERS: 2US FAERS
19Weight decreasedFAERS: 2US FAERS
20AcidosisFAERS: 1US FAERS
21AphasiaFAERS: 1US FAERS
22Cerebrovascular accidentFAERS: 1US FAERS
23Choking sensationFAERS: 1US FAERS
24Depressed Level of ConsciousnessFAERS: 1US FAERS
25DiplopiaFAERS: 1US FAERS
26Drug administered to patient of inappropriate ageFAERS: 1US FAERS
27Drug effect incompleteFAERS: 1US FAERS
28DysarthriaFAERS: 1US FAERS
29EmbolismFAERS: 1US FAERS
30ErythemaFAERS: 1
Canada Vigilance: 1		Canada Vigilance
US FAERS
31Expired product administeredFAERS: 1US FAERS
32False positive investigation resultFAERS: 1US FAERS
33HyperacusisFAERS: 1US FAERS
34HypotensionFAERS: 1US FAERS
35Inappropriate schedule of drug administrationFAERS: 1US FAERS
36Incorrect drug administration durationFAERS: 1US FAERS
37Injection site extravasationFAERS: 1US FAERS
38LacerationFAERS: 1US FAERS
39Liquid product physical issueFAERS: 1US FAERS
40Mitral Valve StenosisFAERS: 1US FAERS
41Olfactory test abnormalFAERS: 1US FAERS
42PhotophobiaFAERS: 1US FAERS
43PneumoniaFAERS: 1US FAERS
44PolyneuropathyFAERS: 1US FAERS
45Product package associated injuryFAERS: 1US FAERS
46ShockFAERS: 1US FAERS
47VasospasmFAERS: 1US FAERS
48VertigoFAERS: 1US FAERS
49Musculoskeletal stiffnessCanada Vigilance: 1Canada Vigilance
50PruritusCanada Vigilance: 1Canada Vigilance
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.